Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer-BioNTech Seek Full Vaccine Approval

Pfizer and BioNTech are seeking full approval for their SARS-CoV-2 vaccine from the US Food and Drug Administration, according to the New York Times. In December, the FDA granted an Emergency Use Authorization for the companies' vaccine, which enabled it to be rolled out across the US.

With a full approval, Pfizer and BioNTech would be able to directly market their vaccine to consumers, and having approval could make it easier for companies, schools, and government agencies to require vaccinations, the Times adds.

CNBC notes that it typically takes the FDA at least a year to determine whether a drug is safe and effective for general use, but adds that Pfizer and BioNTech are seeking approval through a rolling submission process that may be faster as the agency can review data as it receives it.

"We are proud of the tremendous progress we've made since December in delivering vaccines to millions of Americans in collaboration with the US government," Albert Bourla, the CEO and chair of Pfizer, says in a statement. "We look forward to working with the FDA to complete this rolling submission and support their review, with the goal of securing full regulatory approval of the vaccine in the coming months."

The Times adds that FDA is expected to issue an EUA allowing the Pfizer-BioNTech vaccine to be given to 12- to 15-year-olds.

Moderna, CNBC says, is also expected to seek full approval for its vaccine later this month.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.